SEC Form 4 · accession 0001209191-19-015894
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neal Walker
Officer — President and CEO · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 4, 2019 · 6:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F2 | — | Mar 1, 2019 | A | 384,600 | A | — | — | Common Stock | 384,600 | 384,600 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F2The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.